NCT03549754

iCaReMe Global Registry

Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 35,000 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases

Detailed description

The registry intends to provide real world data on patient management and quality of care for patients with T2DM, hypertension, heat failure and chronic kidney disease in clinical practice in many countries. To bridge this gap an observational voluntary registry is set up to capture real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart Failure and Chronic Kidney Disease. Multinational, observational registry utilizing a cloud-based eCRF, for prospective and retrospective data collection, accessible to investigators and Scientific Committee. This registry will be open to all physicians managing T2DM, HTN, HF or CKD across the world

Conditions

• Type 2 Diabetes
• Hypertension
• Chronic Kidney Disease
• Heart Failure

Timeline

• Start date: 2018-02-17
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2018-06-08
• Last updated: 2025-12-09

Locations

55 sites across 15 countries: Brazil, Chile, Côte d’Ivoire, Hong Kong, India, Iraq, Kazakhstan, Kenya, Malaysia, Mexico, Nigeria, South Africa, Taiwan, Ukraine, United Arab Emirates